The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: A systematic review and economic evaluation

Health Technology Assessment

Volumn 18, Issue 65, 2014, Pages 1-202

  Hartwell, Debbie ^a   Cooper, Keith ^a   Frampton, Geoff K ^a   Baxter, Louise ^a   Loveman, Emma ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; BEST SUPPORTIVE CARE; BLOOD TOXICITY; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULARY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; IRRITABILITY; LEUKOPENIA; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LYMPHATIC SYSTEM DISEASE; MIXED INFECTION; MYALGIA; NATIONAL HEALTH SERVICE; NAUSEA; NEURASTHENIA; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SIDE EFFECT; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; VIRUS LOAD; VOMITING; WATCHFUL WAITING; CHILD DEVELOPMENT; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; ECONOMICS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; LIVER; MALE; PATHOLOGY; PRESCHOOL CHILD; PROBABILITY; STATISTICAL MODEL;

ADOLESCENT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; MALE; MARKOV CHAINS; MODELS, ECONOMETRIC; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 84912013981     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18650     Document Type: Article

References (100)

1. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005; 11: 86-94. http://dx. doi. org/10. 1111/j. 1469-0691. 2004. 01061. x.
2. Flamm SL. Chronic hepatitis C virus infection. JAMA 2003; 289: 2413-17. http://dx. doi. org/10. 1001/jama. 289. 18. 2413.
3. Health Protection Agency. Hepatitis C in the UK: 2008 Report. London: Health Protection Agency Centre for Infections; 2008.
4. Davison SM, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child 2006; 91: 781-5. http://dx. doi. org/10. 1136/adc. 2005. 081877.
5. Wirth S, Kelly D, Sokal E, Socha P, Mieli-Vergani G, Dhawan A, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2011; 52: 233-7. http://dx. doi. org/10. 1097/MPG. 0b013e3181f6f09c.
6. Robinson JL, Doucette K. The natural history of hepatitis C virus infection acquired during childhood. Liver Int 2012; 32: 258-70. http://dx. doi. org/10. 1111/j. 1478-3231. 2011. 02633. x.
7. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18: 99-104. http://dx. doi. org/10. 3748/wjg. v18. i2. 99.
8. Roy A, Schwarz K. Hepatitis C in Children. Oregon City, OR: Hepatitis C Choices, Caring Ambassadors Program, Inc.; 2008.
9. Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223-9. http://dx. doi. org/10. 1053/jhep. 2001. 25885.
10. Health Protection Agency. Hepatitis C in the UK: 2011 Report. London: Health Protection Agency; 2011.
11. Hu J, Doucette K, Hartling L, Tjosvold L, Robinson J. Treatment of hepatitis C in children: a systematic review. PLoS ONE 2010; 5: e11542. http://dx. doi. org/10. 1371/journal. pone. 0011542.
12. Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900-7. http://dx. doi. org/10. 1053/j. gastro. 2008. 02. 082.
13. Harris HE, Mieli-Vergani G, Kelly D, Davison S, Gibb DM, Ramsay ME, et al. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr 2007; 45: 335-41. http://dx. doi. org/10. 1097/MPG. 0b013e3180dc9337.
14. Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, et al. Chronic hepatitis C infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36: 275-80. http://dx. doi. org/10. 1086/345908.
15. Rumbo C, Fawaz RL, Emre SH, Suchy FJ, Kerkar N, Morotti RA, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr 2006; 43: 209-16. http://dx. doi. org/10. 1097/01. mpg. 0000228117. 52229. 32.
16. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infancts, children and adolescents. JPGN 2012; 54: 838-55. http://dx. doi. org/10. 1097/MPG. 0b013e318258328d.
17. Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 2004; 19: 1357-62. http://dx. doi. org/10. 1111/j. 1440-1746. 2004. 03463. x.
18. England K, Thorne C, Harris H, Ramsay M, Newell ML. The impact of mode of acquisition on biological markers of paediatric hepatitis C virus infection. J Viral Hepatitis 2011; 18: 533-41. http://dx. doi. org/10. 1111/j. 1365-2893. 2011. 01128. x.
19. Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J 2011; 30: 983-5. http://dx. doi. org/10. 1097/INF. 0b013e318236ac37.
20. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11(11).
21. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5. http://dx. doi. org/10. 1002/hep. 1840010511.
22. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9. http://dx. doi. org/10. 1016/0168-8278(95) 80226-6.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93. http://dx. doi. org/10. 1002/hep. 510240201.
24. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-12. http://dx. doi. org/10. 1002/hep. 510270132.
25. Akobeng AK, Davison S. Quality of life of patients with chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2000; 30: 224-6. http://dx. doi. org/10. 1097/00005176-200002000-00028.
26. Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 2008; 23: 226-30. http://dx. doi. org/10. 1111/j. 1440-1746. 2007. 04859. x.
27. Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48: 341-7. http://dx. doi. org/10. 1097/MPG. 0b013e318185998f.
28. Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology 2011; 53: 1468-75. http://dx. doi. org/10. 1002/hep. 24248.
29. Zacks S, Beavers K, Theodore D, Dougherty K, Batey B, Shumaker J, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol 2006; 40: 220-4. http://dx. doi. org/10. 1097/00004836-200603000-00009.
30. Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshøj LH, Riisom K, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 36-42. http://dx. doi. org/10. 1016/j. jhep. 2010. 01. 033.
31. Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006; 148: 353-8. http://dx. doi. org/10. 1016/j. jpeds. 2005. 10. 031.
32. National Institute for Health and Care Excellence (NICE). Interferon alfa (Pegylated and Non-pegylated) and Ribavirin for the Treatment of Chronic Hepatitis C. Technology Appraisal Guidance No. 75. London: NICE; 2000. URL: http://publications. nice. org. uk/interferon-alfapegylated-and-non-pegylated-and-ribavirin-for-the-treatment-of-chronic-hepatitis-ta75/guidance (accessed 21 May 2012).
33. National Institute for Health and Care Excellence (NICE). Peginterferon alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C. Technology Appraisal Guidance No. 106. London: NICE; 2006. URL: http://publications. nice. org. uk/peginterferon-alfa-and-ribavirin-for-the-treatment-ofmild-chronic-hepatitis-c-ta106 (accessed 21 May 2012).
34. National Institute for Health and Care Excellence (NICE). Peginterferon alfa and Ribavirin for the Treatment of Chronic Hepatitis C. Technology Appraisal Guidance No. 200 (part review of TA75 and TA106). London: NICE; 2010. URL: http://publications. nice. org. uk/peginterferon-alfa-andribavirin-for-the-treatment-of-chronic-hepatitis-c-ta200 (accessed 21 May 2012).
35. Scottish Intercollegiate Guidelines Network (SIGN). Management of Hepatitis C. A National Clinical Guideline. Edinburgh: SIGN; 2006.
36. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antiviral Ther 2004; 9: 491-7.
37. Roche Products Limited. Summary of Product Characteristics-Peginterferon alfa-2a (Pegasys). European Medicines Agency; 2012. URL: www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/human/medicines/000395/human_med_000974. jsp&mid=WC0b01ac058001d124 (accessed 21 May 2012).
38. Merck Sharp & Dohme Limited. Summary of Product Characteristics-Peginterferon alfa-2b (ViraferonPeg). European Medicines Agency; 2012. URL: www. ema. europa. eu/ema/index. jsp? curl=pages/medicines/human/medicines/000329/human_med_001142. jsp&mid=WC0b01ac 058001d124 (accessed 21 May 2012).
39. Merck Sharp & Dohme Limited. Summary of Product Characteristics-Ribavirin (Rebetol). European Medicines Agency; 2012. URL: www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/human/medicines/000246/human_med_001017. jsp&mid=WC0b01ac058001d124 (accessed 21 May 2012).
40. Roche Products Limited. Summary of Product Characteristics-Ribavirin (Copegus). Electronic Medicines Compendium; 2012. URL: www. medicines. org. uk/EMC/medicine/10081/SPC/Pegasys ±135mcg±and±180mcg±±solution±for±injection±in±Pre-filled±Syringe±Pre-filled±Pen/(accessed 21 May 2012).
41. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011; 15(17). http://dx. doi. org/10. 3310/hta15170.
42. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha 2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review. Health Technol Assess 2004; 8(39).
43. Centre for Reviews and Dissemination (CRD). Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. 3rd edn. York: York Publishing Services Ltd; 2009.
44. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-83. http://dx. doi. org/10. 1136/bmj. 313. 7052. 275.
45. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8(36).
46. Al Ali J, Owayed S, Al-Qabandi W, Husain K, Hasan F. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010; 9: 156-60.
47. Ghaffar TY, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AY. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 2009; 76: 895-8. http://dx. doi. org/10. 1007/s12098-009-0187-x.
48. Jara P, Hierro L, de la Vega A, Diaz C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27: 142-8. http://dx. doi. org/10. 1097/INF. 0b013e318159836c.
49. Murray KF, Rodrigue JR, Gonzalez-Peralta RP, Shepherd J, Barton BA, Robuck PR, et al. Design of the PEDS-C trial: pegylated interferon +/-ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007; 4: 661-73. http://dx. doi. org/10. 1177/1740774507085445.
50. Narkewicz MR, Rosenthal P, Schwarz KB, Drack A, Margolis T, Repka MX, et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr 2010; 51: 183-6. http://dx. doi. org/10. 1097/MPG. 0b013e3181b99cf0.
51. Pawlowska M, Pilarczyk M, Halota W. Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16: CR616-21.
52. Pawlowska M, Pilarczyk M, Halota W, Jendryczka E. Virological response to treatment with pegylated interferon alfa-2b and ribavirin chronic hepatitis C in children. Hepatology 2008; 48: 855A-6A.
53. Rodrigue JR, Balistreri WF, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Peginterferon alfa-2a with or without ribavirin results in minimal effect on quality of life, emotional, and cognitive outcomes: Results of the Peds-C trial. Hepatology 2009; 50: 418A.
54. Rosenthal P, Mohan P, Barton B, Robuck PR, Schwarz KB. Incidence of neutropenia and impact on sustained virological response (Svr) in children and adolescents with chronic hepatitis C treated with peginterferon with or without ribavirin: the Peds-C experience. Hepatology 2008; 48: 1031A-2A.
55. Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber B, Jonas MM, et al. Peginterferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the Peds-C trial. Hepatology 2008; 48: 418A.
56. Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-8. http://dx. doi. org/10. 1053/j. gastro. 2010. 10. 047.
57. Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-31. http://dx. doi. org/10. 1016/j. jhep. 2010. 01. 028.
58. Wirth S, Ribes-Koninckx C, Bortolotti F, Zancan L, Jara P, Shelton MM, et al. Children with HCV infection show high sustained virologic response rates on peginterferon alfa-2b plus ribavirin treatment. Hepatology 2008; 48: 392A-3A.
59. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-7. http://dx. doi. org/10. 1016/j. jhep. 2010. 01. 016.
60. National Institute for Health and Care Excellence (NICE). Peginterferon alfa and Ribavirin for the Treatment of Chronic Hepatitis C in Children and Young People [ID373]: Final Scope. London: NICE; 2012.
61. Schwarz KB. PEDS-C: Pegylated Interferon +/-Ribavirin for Children with Hepatitis C. ClinicalTrials. gov study details, 2011. URL: www. clinicaltrials. gov/ct2/show/NCT00100659? term=PEDS-C&rank=1 (accessed 21 May 2012).
62. Jonas MM, Balistreri W, Gonzalez-Peralta RP, Haber B, Lobritto S, Mohan P, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology 2012; 56: 523-31. http://dx. doi. org/10. 1002/hep. 25690.
63. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-18. http://dx. doi. org/10. 1002/hep. 20661.
64. Zhang HF, Yang XJ, Zhu SS, Dong Y, Chen DW, Jia WZ, et al. [An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C.] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2005; 19: 185-7.
65. Sluzewski W, Kowala-Piaskowska A, Wysocki J, Figlerowicz M, Gorczyca A, Halota W, et al. Treatment of chronic hepatitis C in children with pegylated interferon alpha2a and ribavirin-a multi-center study. Acta Poloniae Pharm 2012; 69: 319-26.
66. Abdel-Hady MM, Bansal S, Davison S, Brown MP, Tizzard S, Mulla S, et al. UK experience of treatment of chronic viral hepatitis C in children and adolescents: predictors of viral response and quality of life. Hepatology 2010; 52: 780A.
67. Mernagh P, Norris S, Del CM. Anti-viral treatment of chronic hepatitis C in a paediatric population: a cost-effectiveness analysis. Value Health 2011; 7: PA403. http://dx. doi. org/10. 1016/j. jval. 2011. 08. 935.
68. Sinha M, Das A. Cost-effectivness analysis of different strategies of managment of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000; 19: 23-30. http://dx. doi. org/10. 1097/00006454-200001000-00006.
69. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2008.
70. Bjornsson E, Verbaan H, Oksanen A, Fryden A, Johansson J, Friberg S, et al. Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol 2009; 44: 878-87. http://dx. doi. org/10. 1080/00365520902898135.
71. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-8. http://dx. doi. org/10. 1111/j. 1572-0241. 2003. 07332. x.
72. Thompson-Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11(34).
73. Curtis L. Unit Costs of Health and Social Care 2009. Canterbury: PSSRU, University of Kent; 2010.
74. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 63. London: BMA and RPS; 2012.
75. Guido M, Bortolotti F, Leandro G, Jara P, Hierro L, Larrauri J, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003; 98: 660-3. http://dx. doi. org/10. 1111/j. 1572-0241. 2003. 07293. x.
76. Saigal S, Rosenbaum P, Stoskopf B, Hoult L, Furlong W, Feeny D, et al. Comprehensive assessment of the health status of extremely low birth weight children at eight years of age: comparison with a reference group. J Pediatr 1994; 125: 411-17. http://dx. doi. org/10. 1016/S0022-3476(05)83288-3.
77. Ara R, Brazier J. Populating an Economic Model with Health State Utility Values: Moving Towards Better Practice. HEDS discussion paper 9. Sheffield: University of Sheffield; 2009.
78. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31. http://dx. doi. org/10. 1002/hep. 22375.
79. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
80. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72. http://dx. doi. org/10. 1053/gast. 1997. v112. pm9024300.
81. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-32. http://dx. doi. org/10. 1136/gut. 52. 3. 425.
82. Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10(21).
83. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108. http://dx. doi. org/10. 1097/00005650-199711000-00002.
84. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M. Assessing health-related quality of life pre-and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002; 8: 263-70. http://dx. doi. org/10. 1053/jlts. 2002. 31345.
85. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. Centre for Health Economics discussion paper 172. York: Centre for Health Economics, University of York; 1999.
86. Department of Health. NHS Reference Costs 2010-2011. URL: www. dh. gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_122803 (accessed 16 December 2011).
87. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 64. London: BMA and RPS; 2012.
88. Wang Y, Moss J, Thisted R. Predictors of body surface area. J Clin Anesth 1992; 4: 4-10. http://dx. doi. org/10. 1016/0952-8180(92)90111-D.
89. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51: 1176-84. http://dx. doi. org/10. 1002/hep. 23504.
90. Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, et al. A comparison of peginterferon alfa-2a and alfa-2b for treatment-naive patients with chronic hepatitis C virus: a meta-analysis of randomized trials. Clin Ther 2010; 32: 1565-77. http://dx. doi. org/10. 1016/j. clinthera. 2010. 08. 009.
91. Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47: 836-43. http://dx. doi. org/10. 1002/hep. 22094.
92. Merck Sharp & Dohme Limited. Peginterferon alfa and Ribavirin for the Treatment of Chronic Hepatitis C in Children and Young People Aged 3-17 Years: Manufacturer Submission of Evidence. London: NICE; 2012.
93. Cesaro S, Bortolotti F, Petris MG, Brugiolo A, Guido M, Carli M. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer 2010; 55: 108-12.
94. Iorio R, Giannattasio A, Sepe A, Terracciano LM, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005; 41: 1431-7. http://dx. doi. org/10. 1086/497141.
95. Fioredda F, Moser A, Bertoluzzo L, Lackner H, Giacchino R, La SM, et al. Natural course of HCV infection in childhood cancer survivors. Support Care Cancer 2010; 18: 1413-20. http://dx. doi. org/10. 1007/s00520-009-0763-7.
96. Kage M, Fujisawa T, Shiraki K, Tanaka T, Fujisawa T, Kimura A, et al. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology 1997; 26: 771-5. http://dx. doi. org/10. 1002/hep. 510260333.
97. Roche Products Limited. Peginterferon alfa-2a and Ribavirin for the Treatment of Paediatric Chronic Hepatitis C. Manufacturer Submission of Evidence. London: NICE; 2012.
98. European Paediatric Hepatitis C Virus Network. A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192: 1872-9. http://dx. doi. org/10. 1086/497695.
99. Barshes NR, Udell IW, Lee TC, O'Mahony CA, Karpen SJ, Carter BA, et al. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transp 2006; 12: 1119-23. http://dx. doi. org/10. 1002/lt. 20793.
100. Office for National Statistics (ONS). Deaths Registered in England and Wales in 2010 By Cause. Statistical Bulletin. URL: www. ons. gov. uk.